by 
Hematopoietic stem cell transplantation (HSCT) involves transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood. It is largely being adopted for the treatment of blood cancers such as leukemia, lymphoma, myeloma, and other hematological disorders in addition to non-malignant disorders. The global HSCT market is witnessing significant growth owing to the growing geriatric population susceptible to hematological disorders and increasing number of HSCT procedures performed globally.
The global hematopoietic stem cell transplantation (HSCT) Market is estimated to be valued at US$ 2.88 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growing Number of HSCT Procedures Globally (refered from heading): The number of HSCT procedures has increased considerably over the past few years owing to rising prevalence of hematological disorders and cancers. According to the statistics published by World Marrow Donor Association (WMDA), over 80,000 HSCT procedures are performed annually across the world. Furthermore, National Marrow Donor Program (NMDP) reported that around 9,000 HSCT procedures were performed in the U.S. in 2020. This growing volume of HSCT procedures globally is expected to propel growth of the hematopoietic stem cell transplantation market over the forecast period.
Increasing Geriatric Population (the second driver): The risk of developing hematological disorders rises with age. The geriatric population aged 65 years and above is more prone to develop blood cancers such as leukemia and myeloma. According to the U.S. Census Bureau, the global geriatric population is expected to reach 1.5 billion by 2050. This surging geriatric population base is anticipated to drive the demand for HSCT over the forecast period.
Segment Analysis
The hematopoietic stem cell transplantation (HSCT) market can be segmented based on cell source into autologous and allogenic. The allogenic segment dominates the market with over 60% share as it is considered the gold standard treatment for many hematologic malignancies and genetic disorders.
PEST Analysis
Political: Regulations around HSCT procedures and clinical trials are well defined by regulatory bodies like FDA and EMA to ensure safety and efficacy.
Economic: Developing regions in Asia Pacific and Latin America are witnessing increasing healthcare investments to provide better cancer treatment options including HSCT to more patients.
Social: Growing cancer burden and increasing awareness about advanced treatment options like HSCT is driving more patients and families to opt for HSCT.
Technological: Advancements in stem cell biology, HLA matching techniques, and supportive care have increased survival rates of HSCT and expanded its eligible patient pool.
Key Takeaways
The global hematopoietic stem cell transplantation (HSCT) market is expected to witness high growth over the forecast period driven by increasing cancer prevalence, growing investment in cellular therapy research, and favorable reimbursement scenario in developed countries. The global hematopoietic stem cell transplantation (HSCT) Market is estimated to be valued at US$ 2.88 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030.
The North America region currently dominates the HSCT market supported by presence of major market players, rising healthcare expenditure, and access to advanced treatment options. The Asia Pacific region is expected to grow at the fastest pace led by China, Japan, and India on back of expanding health coverage, low treatment costs, and government initiatives to increase healthcare access.
Key players operating in the hematopoietic stem cell transplantation (HSCT) market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
